Towa Pharmaceutical Co., Ltd.
TWAPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.28B
Close$
$-17.23
166.3% downside
Current Fair Value
166.3% downsideOvervalued by 166.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.28 Billion |
|---|---|
| Enterprise Value | $187.62 Billion |
| Annual dividend | $0.51 |
| Dividend yield | 2.27% |
| Earnings per Share | $107.05 |
| Beta | -0.09 |
| Outstanding Shares | 49,228,000 |
Return
| Return on Equity | 4.55% |
|---|---|
| Return on Assets | 1.73% |
| Return on Invested Capital | 7.34% |
Valuation & Multiples
| P/E Ratio | 20.96 |
|---|---|
| PEG | 17.68 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 0.67 |
| Enterprise Value to EBIT | 6.73 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 1.22 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$438.90 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$0.64
Consensus analyst estimateRevenue Estimate
$450.44 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Towa Pharmaceutical Co., Ltd.
4,923 employees
CEO: Itsuro Yoshida
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmace...